NASDAQ
Black Diamond Therapeutics, Inc. (BDTX) has a free cash flow growth of -50.76% as of Friday, May 29, 2026. This represents a 155.56% decrease compared to its 12-month average of 91.36%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.